AzTrials
AzTrials

Parkinson DiseaseNCT03079960

Data-Driven Characterization of Neuronal Markers During Deep Brain Stimulation for Patients With Parkinson's Disease

A study testing Electrophysiological recording and measurement devices in people with Parkinson Disease, run by Prof. Dr. Volker Arnd Coenen at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has developed into a standard therapy in the refractory stage of Parkinson's disease (PD). Implanted micro- and macroelectrodes can be used to derive neural signals from the basal ganglia (BG). Read more about this study

Who is it for?
Ages 35 to 75 years
Conditions the study is for
Parkinson Disease
What is being tested?
Electrophysiological recording and measurement devices
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteGermany
Study dates
4 Apr 2017to 30 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female patients aged ≥ 35 and ≤ 75 years
  • Patients with diagnosed PD according to UK PDS Brain Bank Criteria.
  • Written informed consent.
  • For PG-O and PG-pre, patients who are eligible for STN DBS Surgery according to the guidelines of the DGN (www.dgn.org)
  • For PG-chronic, patients who have received permanent DBS implantation in the past and who use the DBS treatment.

Who cannot join

  • MR Imaging shows a contraindication for microelectrode recordings. If imaging shows a high amount of blood vessels in the target region and no safe trajectory for inserting the microelectrode can be found, then the patient may receive implantation of the macroelectrode without preceding microelectrode measurements, but is excluded from the study.
  • Contraindication for stereotactical neurosurgery.
  • Dementia (Mattis Dementia Rating Score ≤ 130)
  • Acute psychosis stated by a psychiatric physician
  • Unable to give written informed consent
  • Surgical contraindications
Show all 15Show fewer
  • Medications that are likely to cause interactions in the opinion of the investigator
  • Fertile women not using adequate contraceptive methods: female condoms, diaphragm or coil, each used in combination with spermicides; intra-uterine device; hormonal contraception in combination with a mechanical method of contraception;
  • Current or planned pregnancy, nursing period
  • Contraindications according to device instructions or Investigator's Brochure:
  • Diathermy (shortwave, microwave, and/or therapeutic ultrasound diathermy)
  • Magnetic Resonance Imaging (MRI)
  • Patient incapability
  • Patients to be expected poor surgical candidates
  • For PG-chronic, only exclusion criteria 3, 4, 5, 7, 8, 9, 10 are applicable, since electrodes are already implanted, thus, no surgical procedure is necessary.

Trial locations and contacts

1 site in 1 country.

Germany1 site, 1 recruiting
  • Medical Center - University of Freiburg - Clinic for Neurosurgery - Dept. of Stereotactical and Functional Neurosurgery

    Freiburg im Breisgau, Baden-Wurttemberg, 79106

    Michael Tangermann, Dr., +49 761 203 ext. 8423, michael.tangermann@blbt.uni-freiburg.de

    Volker Arnd Coenen, Prof. Dr., +49 761 270 ext. 50630, stereo@uniklinik-freiburg.de

    Recruiting

Other trials in Germany

About this study

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has developed into a standard therapy in the refractory stage of Parkinson's disease (PD). Implanted micro- and macroelectrodes can be used to derive neural signals from the basal ganglia (BG). Cortical signals can be obtained by measurements of the electroencephalogram (EEG) or the electrocorticogram (ECoG). Both signal types can be used to characterize the motor system of the patient and make it possible to estimate the effectiveness of a currently performed DBS. However, the relationship between such neuronal features on the one hand and the DBS stimulation parameters or the observable clinical effects on the other hand is very individual and varies from patient to patient.

The aim of the present study is to: (1) determine neuronal characteristics that are informative about the clinically relevant motor status of PD patients. (2) The investigation and description of the complex non-stationary dynamics of neuronal characteristics as a consequence of changing DBS stimulation parameters. (3) The study of the effect of changing DBS stimulation parameters on motor performance.

The three objectives form an important building block for future adaptive closed-loop DBS strategies (aDBS). Here, the stimulation parameters are to be adapted in the single-trial and depending on the currently detected motor state of the patient. Since this is accessible only to a very limited extent, it is to be investigated whether information about the motor state can be obtained from the neural features.

Read the detailed description

Deep brain stimulation of the subthalamic nucleus (STN DBS) has developed into a standard therapy for treating refractory stages of Parkinson's disease (PD). The large number of DBS systems nowadays routinely implanted represent open loop technology. These so-called continuous DBS (cDBS) systems are relatively simple from a technical perspective, as they deliver uninterrupted high-frequency stimulation pulse trains typically 24 hours a day. The stimulation is applied to the target area, like the STN, without taking into account the current level of PD symptoms or the motor state of the patient. Changes to the stimulation parameters -like pulse width, amplitude or frequency- can be applied only by a trained expert during a so-called adjustment session, which usually takes place in the clinic. This limits the number of adjustment sessions to at most a few per year. This may be sufficient to adapt the system to long-term changes of a patient's state as induced by PD progress, which take place over months and years, but certainly is not sufficient to react upon varying daily conditions or changes on even smaller temporal scales. Despite being a widely accepted approach, cDBS is known to cause several side effects such as speech impairment or tolerance to treatment due to chronic continuous stimulation, and has disadvantages with regard to energy efficiency and battery life of the implanted stimulation device.

In contrast to the available cDBS systems, it would be desirable to have adaptive DBS (aDBS) systems, that provide stimulation on demand only and, for example, reduce or stop stimulation delivery during periods of inactivity or when the motor performance of the patient is sufficiently high. Even though a few aDBS prototypes have been reported in literature, they are investigated in research contexts only and have not yet been included into clinical routines.

To realize the closed loop control of a patient's motor symptoms by an aDBS approach, at least one information source describing the motor state of the patient is required. On the one hand, this information may be accessible via external sensors or wearables, which record e.g. muscle tone, tremor, kinematic information etc. in every-day situations or during the execution of specific motor tasks. Alternatively, the information may also be expressed by specific brain signals, so-called neural markers, which correlate with the motor state and can act as its surrogate.

Informative neural markers can be extracted from several brain areas and with different recording technologies. Activity in the subthalamic nucleus (STN) and other basal ganglia can be measured both during and after the implantation of the DBS electrodes in the form of local field potentials (LFP) or microelectrode recordings (MER). Signals recorded either during stimulation, from small time windows between stimulation sequences, or with stimulation absent can provide information about the clinically relevant motor state of PD patients. Additionally, it has been shown that neural signal recordings via magneto- or electroencephalogram (MEG/EEG) and electrocorticogram (ECoG) may provide valuable complementary information compared to the signals obtained from basal ganglia.

On a clinical level, the motor state of the patients can be assessed using part III of the Unified Parkinson's Disease Rating Scale (UPDRS-III) test battery. Its assessment, however, is rather time consuming and requires the involvement of a clinician (neurologist) and consequently the full UPDRS-III score cannot be used for a aDBS implementation. Unfortunately, with the current state of research, the information about the motor behavior cannot simply be replaced by information collected via brain signals. The reasons is, that the relation between relevant neural markers of the LFP and MER recordings, and the individual motor symptoms (e.g. as described by the UPDRS-III) is far from complete and requires further investigation.

To characterize candidates of neural markers, which can be utilized as surrogates for the motor state, it is important to investigate two questions: (1) (How) does the marker change upon applying DBS? (2) Is this change related to the clinical effects of DBS observed e.g. a change in the UPDRS-III score? In this context, selected oscillatory components have been described. The power of LFP oscillatory components in the beta range (12-30 Hz) has been reported to drop upon DBS and, despite unclear causal relation and action mechanisms, it has also been correlated to motor parkinsonian symptoms as bradykinesia and rigor. Furthermore, the interaction of band power of other frequency components with specific PD motor symptoms has been described. An example is the relation between the delta and gamma band power recorded from the STN with dyskinetic symptoms and the correlation of high gamma band power with UPDRS-III scores, and the modulation of high gamma through DBS or L-Dopa. Additionally, DBS stimulation has also been observed to influence cross-frequency coupling between cortical-cortical, cortical-subcortical and subcortical-subcortical structures.

Most studies on the effect of DBS on the motor system and on informative neural markers report on global effects observed in group studies. However, grand average findings may not provide sufficient information to control aDBS systems for an individual patient. This is underlined by many recent studies from the field of brain-computer interfaces (BCI), where informative neural signatures have been found to be subject-specific, and where subject-specific methods for extracting informative neural markers have been applied successfully. Hence we propose to refine the level of data analysis beyond the level of group statistics.

Apart from neural markers being subject-specific, the implicit dynamics of both, the neural markers and the DBS effects, should be considered:

  • Dynamics of the neural markers Even within an individual user and a single day, the adaptation of DBS parameters may be required in order to compensate non-stationary characteristics displayed by neural markers on several temporal scales : (a) On the scale of hours to minutes, due to, e.g., changes in wakefulness/tiredness or circadian cycle. (b) On the scale of minutes to seconds, variations e.g. in the attention level, workload. (c) On even smaller time scales due to the current status of the motor system (task preparation vs. task onset vs. sustained ongoing tasks, high force vs. precision tasks, isometric vs. movement tasks etc.). It must be expected, that the individually informative neural markers, which can be exploited to realize the closed-loop aDBS system, are subject to change their informative content in the above-mentioned time scales and scenarios.
  • Dynamics of the DBS effects Depending on the DBS parameters (e.g. intensity, frequency, duration, pulse shape) of the stimulation pattern applied in the immediate past, the effects onto (1) the motor system and onto (2) the informative neural markers are known to persist from several seconds to minutes even after stimulation has been turned off [Bronte-Stewart et al. 2009]. Due to this washout effect of DBS, the stimulation strategy of an aDBS system will probably benefit from taking the (short term) stimulation history into account. The duration and temporal dynamics of this so-called washout period depends on the kind of motor symptom studied. It has been reported to be longer for akinesia (minutes - hours) as opposed to rigidity (minutes). Thus it can be hypothesized, that the dynamics of the washout effects for the motor symptoms and for the neural markers are not the same.

The applicants of this proposal want to make a substantial step forward into the direction of a fully closed-loop aDBS system. To reach this goal, it is necessary to develop data analysis methods for brain signals, which are capable of identifying the aforementioned informative neural markers, and to utilize them as input to decode the current motor state. For both tasks, machine learning methods have been successfully investigated and utilized in the context of closed loop BCI systems. Methods developed in this field allow for single-trial decoding of non-invasive EEG signals and invasive signals like ECoG and LPF. The machine learning methods enable the detection of movement intentions in single-trial and the decoding imagined or executed movements. Furthermore, latest research of the applicants has shown, that BCI approaches allow to even predict the task performance of an upcoming motor task, which may be valuable information for brain state dependent closed-loop applications.

Being tested
Electrophysiological recording and measurement devices
Keywords
Parkinson, DBS, Deep Brain Stimulation, LFP, Local Field Potentials, EEG, Electroencephalogram
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Electrophysiological recording and measurement devicesDevice

    Also called AlphaOmega Recording and Stimulation System, Leadpoint Recording and Stimulation System, BrainAmp Amplifier

    Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.

Study groups in NCT03079960
Study groupRoleWhat they receive
Original patient group (PG-O)ExperimentalDBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study. Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks. The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure.
Receives: Device: Electrophysiological recording and measurement devices
Chronic patient group (PG-chronic)No interventionPatients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes. Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O.
Preoperative patient group (PG-pre)No interventionPatients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study. During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes. The behavioral tests performed for PG-pre are the same as conducted for PG-O.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation of stimulation parameters and motor performance

    For each patient, a linear regression model will be trained to predict motor performance (target variable) given a stimulation parameter set (predictor). The r-value of each of the trained models across all subjects will be compared against the r-values obtained from resampled bootstrap models. Statistical significant differences between estimated and bootstrapped models will be assessed by a Wilcoxon test with a significance level of 5%. Endpoint is prediction of motor performance as assessed by the r-values of the estimated models.

    Stimulation parameters will include current (mA), frequency (Hz) and impulse width (µs). Motor performance will be evaluated by various motor tests (comparable to UPDRS).

    Measured: Days 1-4 after neurosurgery

Secondary outcomes (2)
  1. Correlation of motor performance and informative neural markers

    For each patient, the Pearson correlation between (1) the beta band power and the performance in the short motor tasks and (2) the best multivariate neural marker obtained by our models with the performance in the short motor tasks will be computed. The correlations obtained across all subjects will then be compared under the two conditions. Statistical significant difference between multivariate and beta markers will be estimated by a pairwise Wilcoxon test (significance level of 5%). Endpoint is prediction of motor performance as assessed by the r-values of the estimated models.

    Motor performance will be evaluated by various motor tests (comparable to UPDRS) and beta band frequency levels. Informative neural markers will be assessed by electroencephalograms (EEG), electromyelograms (EMG) and physiological parameters (e.g. respiratory frequency).

    Measured: Days 1-4 after neurosurgery

  2. Correlation of stimulation parameters and informative neural markers

    Analogue to the primary endpoint, a linear regression model is trained, which learns to predict the values of multivariate neural markers based on stimulation parameters. Again, we compare the r-values of the estimated models and of the corresponding models obtained after bootstrap resampling for each subject. Statistical significant differences between them will be assessed by a Wilcoxon test (significance level of 5%). Endpoint is prediction of neural marker values as assessed by the r-values of the estimated models.

    Informative neural markers will be assessed by electroencephalograms (EEG), electromyelograms (EMG) and physiological parameters (e.g. respiratory frequency).

    Measured: Days 1-4 after neurosurgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2017
  2. Study start4 Apr 2017
  3. Primary completion30 Dec 2021 (estimated)
  4. Study completion30 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
The main part of the proposed study has a duration of 2 years and will include up to 20 PD patients who are eligible to receive treatment with STN DBS. This is the interventional arm, this patient group is termed PG-O here onwards. An extension phase of the study, starting in August 2019, will consider two additional groups of patients as controls for the PG-O patient group. Firstly, patients treated chronically with DBS, who underwent DBS implantation surgery months to years ago, termed PG-chronic. Secondly, patients scheduled for DBS implantation but who have not yet been implanted, termed PG-pre. It is intended to recruit approx. n=50 patients into each control group, thus resulting in an overall study cohort size of approx. 20+50+50=120 patients.
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03079960
Sponsor's protocol ID
P001449
Status last verified
Jul 2021
First submitted
28 Feb 2017
Last updated
28 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Androulidakis AG, Kuhn AA, Chen CC, Blomstedt P, Kempf F, Kupsch A, Schneider GH, Doyle L, Dowsey-Limousin P, Hariz MI, Brown P. Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease. Brain. 2007 Feb;130(Pt 2):457-68. doi: 10.1093/brain/awl358. Epub 2007 Jan 8.

    PubMed 17213215
  • Beudel M, Brown P. Adaptive deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(Suppl 1):S123-6. doi: 10.1016/j.parkreldis.2015.09.028. Epub 2015 Sep 15.

    PubMed 26411502
  • Blankertz B, Lemm S, Treder M, Haufe S, Muller KR. Single-trial analysis and classification of ERP components--a tutorial. Neuroimage. 2011 May 15;56(2):814-25. doi: 10.1016/j.neuroimage.2010.06.048. Epub 2010 Jun 28.

    PubMed 20600976
  • Blankertz, B., Tomioka, R., Lemm, S., Kawanabe, M., & Müller, K.-R. (2008). Optimizing spatial filters for robust EEG single-trial analysis. Signal Processing Magazine, IEEE, 25(1), 41-56.

  • Blumenfeld Z, Bronte-Stewart H. High Frequency Deep Brain Stimulation and Neural Rhythms in Parkinson's Disease. Neuropsychol Rev. 2015 Dec;25(4):384-97. doi: 10.1007/s11065-015-9308-7. Epub 2015 Nov 25.

    PubMed 26608605
  • Blumenfeld Z, Velisar A, Miller Koop M, Hill BC, Shreve LA, Quinn EJ, Kilbane C, Yu H, Henderson JM, Bronte-Stewart H. Sixty hertz neurostimulation amplifies subthalamic neural synchrony in Parkinson's disease. PLoS One. 2015 Mar 25;10(3):e0121067. doi: 10.1371/journal.pone.0121067. eCollection 2015.

    PubMed 25807463
  • Borghini G, Astolfi L, Vecchiato G, Mattia D, Babiloni F. Measuring neurophysiological signals in aircraft pilots and car drivers for the assessment of mental workload, fatigue and drowsiness. Neurosci Biobehav Rev. 2014 Jul;44:58-75. doi: 10.1016/j.neubiorev.2012.10.003. Epub 2012 Oct 30.

    PubMed 23116991
  • Carron R, Chaillet A, Filipchuk A, Pasillas-Lepine W, Hammond C. Closing the loop of deep brain stimulation. Front Syst Neurosci. 2013 Dec 20;7:112. doi: 10.3389/fnsys.2013.00112.

    PubMed 24391555
  • Castano-Candamil S, Meinel A, Dahne S, Tangermann M. Probing meaningfulness of oscillatory EEG components with bootstrapping, label noise and reduced training sets. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:5159-62. doi: 10.1109/EMBC.2015.7319553.

    PubMed 26737453
  • Dahne S, Meinecke FC, Haufe S, Hohne J, Tangermann M, Muller KR, Nikulin VV. SPoC: a novel framework for relating the amplitude of neuronal oscillations to behaviorally relevant parameters. Neuroimage. 2014 Feb 1;86:111-22. doi: 10.1016/j.neuroimage.2013.07.079. Epub 2013 Aug 15.

    PubMed 23954727
  • Engel AK, Fries P. Beta-band oscillations--signalling the status quo? Curr Opin Neurobiol. 2010 Apr;20(2):156-65. doi: 10.1016/j.conb.2010.02.015. Epub 2010 Mar 30.

    PubMed 20359884
  • Hamilton L, McConley M, Angermueller K, Goldberg D, Corba M, Kim L, Moran J, Parks PD, Sang Chin, Widge AS, Dougherty DD, Eskandar EN. Neural signal processing and closed-loop control algorithm design for an implanted neural recording and stimulation system. Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:7831-6. doi: 10.1109/EMBC.2015.7320207.

    PubMed 26738107
  • Castaño-Candamil, S., Meinel, A., Reis, J., Tangermann, M. Correlates to influence user performance in a hand motor rehabilitation task. Clinical Neurophysiology, Volume 126, Issue 8, e166-e167, 2015.

  • Hohne J, Bartz D, Hebart MN, Muller KR, Blankertz B. Analyzing neuroimaging data with subclasses: A shrinkage approach. Neuroimage. 2016 Jan 1;124(Pt A):740-751. doi: 10.1016/j.neuroimage.2015.09.031. Epub 2015 Sep 25.

    PubMed 26407815
  • Jayaram, V., Alamgir, M., Altun, Y., Schölkopf, B., & Grosse-Wentrup, M. Transfer Learning in Brain-Computer Interfaces. arXiv preprint arXiv:1512.00296, 2015.

Questions about this trial

What is this clinical trial studying?

A study testing Electrophysiological recording and measurement devices in people with Parkinson Disease, run by Prof. Dr. Volker Arnd Coenen at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Volker Coenen, Prof. Dr. (+49 761 27050510, volker.coenen@uniklinik-freiburg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation of stimulation parameters and motor performance (time frame: Days 1-4 after neurosurgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03079960, which also lists 42 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in